Table 1 Patient demographics and clinical features , antibodies, tumours in different groups
From: Anti-neuron antibody syndrome: clinical features, cytokines/chemokines and predictors
Total | AE | PNS | No tumour | Tumours | Good outcomes | Poor outcomes | No relapse | Relapses | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | 110 | ###### | 43 | ###### | 67 | ###### | 70 | ###### | 40 | ###### | 73 | (66.36%) | 37 | (33.64%) | 77 | ###### | 33 | ###### | |
Age | <18 years | 26 | ###### | 18 | ###### | 8 | (7.27%) | 24 | ###### | 2 | (1.82%) | 25 | (22.73%) | 1 | (0.91%) | 15 | ###### | 11 | ###### |
≥18 years | 84 | ###### | 25 | ###### | 59 | ###### | 46 | ###### | 38 | ###### | 48 | (43.64%) | 36 | (32.73%) | 62 | ###### | 22 | ###### | |
Sex | Men | 56 | ###### | 19 | ###### | 37 | ###### | 37 | ###### | 19 | ###### | 36 | (32.73%) | 20 | (18.18%) | 40 | ###### | 16 | ###### |
Women | 54 | ###### | 24 | ###### | 30 | ###### | 33 | ###### | 21 | ###### | 37 | (33.64%) | 17 | (15.45%) | 37 | ###### | 17 | ###### | |
Types of onset | Acute | 52 | ###### | 34 | ###### | 18 | ###### | 36 | ###### | 16 | ###### | 43 | (39.09%) | 9 | (8.18%) | 31 | ###### | 21 | ###### |
Sub-acute | 13 | ###### | 4 | (3.64%) | 9 | (8.18%) | 10 | (9.09%) | 3 | (2.73%) | 9 | (8.18%) | 4 | (3.64%) | 9 | (8.18%) | 4 | (3.64%) | |
Chronic | 45 | ###### | 5 | (4.55%) | 40 | ###### | 24 | ###### | 21 | ###### | 21 | (19.09%) | 24 | (21.82%) | 37 | ###### | 8 | (7.27%) | |
MRI Flair/T2 abnormality | No | 66 | ###### | 29 | ###### | 37 | ###### | 41 | ###### | 25 | ###### | 42 | (38.18%) | 24 | (21.82%) | 52 | ###### | 14 | ###### |
Yes | 33 | ###### | 12 | ###### | 21 | ###### | 23 | ###### | 10 | (9.09%) | 23 | (20.91%) | 10 | (9.09%) | 19 | ###### | 14 | ###### | |
EEG/EMG abnormality | No | 7 | (6.36%) | 5 | (4.55%) | 2 | (1.82%) | 5 | (4.55%) | 2 | (1.82%) | 6 | (5.45%) | 1 | (0.91%) | 3 | (2.73%) | 4 | (3.64%) |
Yes | 52 | ###### | 22 | ###### | 30 | ###### | 36 | ###### | 16 | ###### | 34 | (30.91%) | 18 | (16.36%) | 40 | ###### | 12 | ###### | |
CSF leukocytosis | No | 42 | ###### | 15 | ###### | 27 | ###### | 28 | ###### | 14 | ###### | 33 | (30.00%) | 9 | (8.18%) | 28 | ###### | 14 | ###### |
Yes | 41 | ###### | 23 | ###### | 18 | ###### | 28 | ###### | 13 | ###### | 24 | (21.82%) | 17 | (15.45%) | 28 | ###### | 13 | ###### | |
Elevated CSF PRO | No | 53 | ###### | 30 | ###### | 23 | ###### | 38 | ###### | 15 | ###### | 42 | (38.18%) | 11 | (10.00%) | 29 | ###### | 24 | ###### |
Yes | 30 | ###### | 8 | (7.27%) | 22 | ###### | 18 | ###### | 12 | ###### | 15 | (13.64%) | 15 | (13.64%) | 27 | ###### | 3 | (2.73%) | |
CSF abnormality | No | 31 | ###### | 14 | ###### | 17 | ###### | 22 | ###### | 9 | (8.18%) | 25 | (22.73%) | 6 | (5.45%) | 18 | ###### | 13 | ###### |
Yes | 52 | ###### | 24 | ###### | 28 | ###### | 34 | ###### | 18 | ###### | 32 | (29.09%) | 20 | (18.18%) | 38 | ###### | 14 | ###### | |
Anti-neuron antibodies | Anti-NMDAR | 42 | ###### | 42 | ###### | 0 | (0.00%) | 35 | ###### | 7 | (6.36%) | 36 | (32.73%) | 6 | (5.45%) | 23 | ###### | 19 | ###### |
Anti-Hu | 19 | ###### | 0 | (0.00%) | 19 | ###### | 7 | (6.36%) | 12 | ###### | 6 | (5.45%) | 13 | (11.82%) | 14 | ###### | 2 | (1.82%) | |
Anti-Yo | 14 | ###### | 0 | (0.00%) | 14 | ###### | 9 | (8.18%) | 5 | (4.55%) | 6 | (5.45%) | 8 | (7.27%) | 10 | (9.09%) | 4 | (3.64%) | |
Anti-PNMA2 | 12 | ###### | 0 | (0.00%) | 12 | ###### | 8 | (7.27%) | 4 | (3.64%) | 10 | (9.09%) | 2 | (1.82%) | 10 | (9.09%) | 2 | (1.82%) | |
Anti-CV2 | 8 | (7.27%) | 0 | (0.00%) | 8 | (7.27%) | 2 | (1.82%) | 6 | (5.45%) | 4 | (3.64%) | 4 | (3.64%) | 7 | (6.36%) | 1 | (0.91%) | |
Anti-Amphiphysin | 8 | (7.27%) | 0 | (0.00%) | 8 | (7.27%) | 2 | (1.82%) | 6 | (5.45%) | 4 | (3.64%) | 4 | (3.64%) | 7 | (6.36%) | 1 | (0.91%) | |
Anti-SOX1 | 7 | (6.36%) | 0 | (0.00%) | 7 | (6.36%) | 4 | (3.64%) | 3 | (2.73%) | 3 | (2.73%) | 4 | (3.64%) | 5 | (4.55%) | 2 | (1.82%) | |
Others | 7 | (6.36%) | 1 | (0.91%) | 6 | (5.45%) | 4 | (3.64%) | 3 | (2.73%) | 7 | (6.36%) | 0 | (0.00%) | 4 | (3.64%) | 3 | (2.73%) | |
Tumours | Non-small cell lung cancer | 9 | (8.18%) | 0 | (0.00%) | 9 | (8.18%) | 0 | (0.00%) | 9 | (8.18%) | 1 | (0.91%) | 8 | (7.27%) | 9 | (8.18%) | 0 | (0.00%) |
Small cell lung cancer | 6 | (5.45%) | 1 | (0.91%) | 5 | (4.55%) | 0 | (0.00%) | 6 | (5.45%) | 2 | (1.82%) | 4 | (3.64%) | 5 | (4.55%) | 1 | (0.91%) | |
Breast cancer | 5 | (4.55%) | 0 | (0.00%) | 5 | (4.55%) | 0 | (0.00%) | 5 | (4.55%) | 1 | (0.91%) | 4 | (3.64%) | 3 | (2.73%) | 2 | (1.82%) | |
Ovarian teratoma | 3 | (2.73%) | 3 | (2.73%) | 0 | (0.00%) | 0 | (0.00%) | 3 | (2.73%) | 3 | (2.73%) | 0 | (0.00%) | 1 | (0.91%) | 2 | (1.82%) | |
Others | 18 | ###### | 3 | (2.73%) | 15 | ###### | 0 | (0.00%) | 15 | ###### | 9 | (8.18%) | 9 | (8.18%) | 13 | ###### | 5 | (4.55%) | |